Approval in Endometrial Cancer Expanded; Masks at Cancer Centers; NPR Reporter Dies

[MEDPAGE TODAY]( Oncology Update Friday, August 02, 2024 [Approval in Endometrial Cancer Expanded; Masks at Cancer Centers; NPR Reporter Dies]( [FDA Greenlights First Gene Therapy for a Solid Tumor]( [FDA OKs Subcutaneous Daratumumab Plus VRd for Myeloma]( [Gene-Expression Profiling Can Help Improve Outcomes in Cancers of Unknown Primary]( [Aspirin for CRC Risk Reduction May Benefit Unhealthy People Most]( ADVERTISEMENT Exclusives & Features [Physician Fights Insurer to Cover Her Baby's Brain Cancer Treatment]( [How Good Is Wegovy's Heart Benefit?]( [Fauci Tells All on Relationship With Trump]( [Evaluation of CD3 and CD8 T-Cell Immunohistochemistry for Prognostication and Prediction of Benefit From Adjuvant Chemotherapy in Early-Stage Colorectal Cancer Within the QUASAR Trial.]( PURPOSE: High densities of tumor infiltrating CD3 and CD8 T-cells are associated with superior prognosis in colorectal cancer (CRC). Their value as predictors of benefit from adjuvant chemotherapy is... [READ MORE]( [Deep Learning Artificial Intelligence Predicts Homologous Recombination Deficiency and Platinum Response From Histologic Slides.]( PURPOSE: Cancers with homologous recombination deficiency (HRD) can benefit from platinum salts and poly(ADP-ribose) polymerase inhibitors. Standard diagnostic tests for detecting HRD require... [READ MORE]( [Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer.]( PURPOSE: Patients with advanced endometrial cancer (EC) who progress on or after platinum-based therapy and immunotherapy have poor prognosis. We report efficacy and safety of sacituzumab govitecan... [READ MORE]( [A phase I clinical trial of intrahepatic artery delivery of TG6002 in combination with oral 5-fluorocytosine in patients with liver-dominant metastatic colorectal cancer]( Background: Effective treatment for patients with metastatic cancer is limited, particularly for colorectal cancer patients with metastatic liver lesions (mCRC), where accessibility to numerous... [READ MORE]( [Factors influencing pathological complete response and tumor regression in neoadjuvant radiotherapy and chemotherapy for high-risk breast cancer.]( BACKGROUND: Pathological complete response (pCR) is a well-established prognostic factor in breast cancer treated with neoadjuvant systemic therapy (naST). The determining factors of pCR are known to... [READ MORE]( [A Property of Everyday Health group]( © 2024 MedPage Today, LLC. MedPage Today is among the federally registered trademarks of MedPage Today, LLC, and may not be used by third parties without explicit permission. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address: {EMAIL} [Manage Email Preferences]( | [Unsubscribe](lst=NL_Spec_Oncology_Update?xid=nl_mpt_Oncology_update_2024-08-02&mh=3c4cdd242849aa0e970f25e401732f81) | [Terms of Use]( | [Privacy Policy]( Technical Questions: feedback@medpagetoday.com 114 5th Avenue, 15th Floor New York, NY 10011